Q3 2025 Outlook -- Net sales are forecasted at $15.9 million for Q3 2025, representing year-over-year growth of approximately ...

Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd.

Special 250th anniversary designs offer a golden opportunity to grow the hobby and inspire the next generation of ...

USEG READ THE FULL USEG RESEARCH REPORT 2nd Quarter 2025 Financial and Operating Results On August 12, 2025, U.S. Energy (NASDAQ:USEG) reported 2nd quarter 2025 financial and operating results. The ...

Q2 2025 Management View James V. Caruso, President and CEO, stated that Cellectar has made "significant strides across our ...

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Key Points EPS (GAAP) matched estimates at $(0.26), reflecting cost controls but ongoing net losses and no revenue. Positive clinical milestones achieved for BX211 (diabetic foot osteomyelitis) and ...

Clinical trial timelines for key lymphoma and autoimmune disease programs were delayed by approximately two quarters. Cash and investments totaled $302.6 million at the end of Q2 2025, expected to ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell ...

Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the "Company") today reported results for the first quarter fiscal year 2026, which ended June 29, 2025. First ...

Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the 'Company”) today reported results for the first quarter fiscal year 2026, which ended June 29, 2025.